Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
Open Access
- 6 September 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 45 (12), 1732-1740
- https://doi.org/10.1038/bmt.2010.195
Abstract
Refractory chronic GVHD (cGVHD) is an important complication after allogeneic hematopoietic SCT and is prognostic of poor outcome. MSCs are involved in tissue repair and modulating immune responses in vitro and in vivo. From April 2005 to October 2008, 19 patients with refractory cGVHD were treated with MSCs derived from the BM of volunteers. The median dose of MSCs was 0.6 × 106 cells per kg body weight. Fourteen of 19 patients (73.7%) responded well to MSCs, achieving a CR (n=4) or a PR (n=10). The immunosuppressive agent could be tapered to less than 50% of the starting dose in 5 of 14 surviving patients, and five patients could discontinue immunosuppressive agents. The median duration between MSC administration and immunosuppressive therapy discontinuation was 324 days (range, 200–550 days). No patients experienced adverse events during or immediately after MSC infusion. The 2-year survival rate was 77.7% in this study. Clinical improvement was accompanied by the increasing ratio of CD5+CD19+/CD5−CD19+ B cells and CD8+CD28−/CD8+CD28+ T cells. In conclusion, transfusion of MSCs expanded in vitro, irrespective of the donor, might be a safe and effective salvage therapy for patients with steroid-resistant, cGVHD.Keywords
This publication has 41 references indexed in Scilit:
- Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumBone Marrow Transplantation, 2008
- Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in childrenBone Marrow Transplantation, 2007
- Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group ReportTransplantation and Cellular Therapy, 2006
- Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergyPublished by American Society of Hematology ,2005
- Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‐versus‐host diseaseBritish Journal of Haematology, 2005
- Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy PatientsTransplantation and Cellular Therapy, 2005
- Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2005
- Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradationBlood, 2004
- Chronic graft-versus-host disease: A prospective cohort studyTransplantation and Cellular Therapy, 2003
- Repair of Articular Cartilage Defects Using Mesenchymal Stem CellsTissue Engineering, 1995